Company Overview
Sintx Technologies, Inc. operates as an advanced ceramics company dedicated to the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications within the United States. The firm functions within the Healthcare sector, specifically targeting the Medical Devices industry, which implies a focus on specialized equipment and materials used in clinical and diagnostic settings. Sintx Technologies, Inc. holds a market capitalization of $9.40M and generated annual revenue of $1.02M in the trailing twelve months, while the number of employees is listed as N/A. The market cap figure of $9.40M indicates a small-cap enterprise, suggesting limited liquidity and higher volatility compared to larger peers, while the revenue of $1.02M reflects a nascent stage of commercialization where the company is likely prioritizing product development and market penetration over substantial scale. The absence of employee count data further characterizes the company as a specialized entity where capital allocation may be heavily weighted toward R&D rather than large-scale workforce expansion.
Financial Health
The company reported revenue of $1.02M and net income of $-17,083,000 over the trailing twelve months, with EBITDA standing at $-10,227,000. The significant gap between the $1.02M revenue and the $-17,083,000 net income reveals a highly leveraged cost structure where operating expenses, likely driven by R&D and manufacturing overhead, drastically exceed total sales. Free cash flow stands at $-2,919,625, indicating that the company is currently consuming cash reserves to fund its operations and development initiatives rather than generating surplus liquidity. This negative free cash flow suggests a reliance on external financing or existing cash balances to sustain daily activities and growth efforts. The company maintains a gross margin of 45.3%, which indicates that the silicon nitride devices retain a healthy portion of revenue after direct production costs, yet the operating margin of -787.6% and profit margin of 0.0% demonstrate that fixed costs and overhead are severely eroding overall profitability. Total cash on hand is $4.14M, which is insufficient to cover total debt of $3.25M when considering the high leverage implied by the debt-to-equity ratio of 110.92, suggesting the balance sheet is significantly leveraged rather than conservative. The current ratio of 1.51 indicates that the company possesses sufficient current assets to cover its current liabilities, pointing to moderate short-term liquidity despite the heavy debt load. Return on Equity is -303.8% and return on assets is -69.8%, revealing that management effectiveness in generating profit from shareholder equity and total assets is currently negative, a common characteristic for early-stage companies investing heavily in future capabilities.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is -1.07, implying that the market is pricing in future earnings recovery or sustained losses depending on the forecast model used. The price-to-book ratio is 3.09, indicating that the market values the company at a significant premium over its net asset book value, which often reflects investor expectations of future growth in the medical device sector. The price-to-sales ratio is 9.23, and the EV/EBITDA is -0.83, suggesting that traditional valuation multiples are distorted by negative earnings and that investors are relying on sales-based or asset-based metrics to value the enterprise. The 52-week high is $6.78 and the 52-week low is $1.71, and without a specific current price provided in the data, the stock's position within this $5.07 range of fluctuation remains undefined by the available facts. The beta value is 0.67, which means the stock price exhibits lower volatility relative to the broader market, moving less sharply than the overall market index.
Growth & Income
Revenue growth year-over-year is -46.5%, and earnings growth is N/A due to negative earnings in the prior period. The negative revenue growth indicates a contraction in sales, while the inability to calculate earnings growth highlights the volatility of profitability in this developmental stage. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it reinvests any available earnings or cash flow directly into research, development, and commercialization efforts rather than distributing income to shareholders. The overall growth and income profile is characterized by declining revenue, negative earnings, and a lack of dividend distribution, typical of a small-cap medical device company in a high-investment phase.